Bookmark Us and Share :)

Recent FDA Approval of Ribociclib as Upfront Therapy

Say and pronounce Recent FDA Approval on SuperTTS.com Make Your Own Text-To-Speech Words Instantly

  Info

Description

Kimberly L. Blackwell, MD, provides insight on the recent approval of ribociclib and its use as upfront therapy in breast cancer.

Tags

cancer oncology
  Email Video to Friends   Receive Emails for Similar Videos

Email:

  Repeat and Loop Video   Link to Video   Create Short URL  Publish Text About This Video   Share on Facebook, Twitter, and more
  See Recommended Videos For You
Old Cartoons on DVD. Visit and Bookmark: Cool90s.com!

Related

  Dr. Kelly on the FDA Approval of Ribociclib in HR+ Breast Cancer   Combined Immunotherapy and Chemotherapy for NSCLC   Evolving Approaches for Treating ALK-Positive NSCLC   Cancer Advance of the Year, FDA Approval for CINV, Breakthrough Designation in TNBC, And More   Nivolumab Lung Cancer Approval Expanded, Abemaciclib Granted Breakthrough Status, and More   Promising Parkinson's research in San Diego   FDA Approval of Ribociclib for Metastatic Breast Cancer   Niraparib Maintenance for Recurrent Ovarian Cancer   Upfront Immunotherapy + Chemotherapy for NSCLC   Extended Adjuvant Therapy for HER2-Positive Breast Cancer   FDA Approval of Brigatinib for ALK+ NSCLC   FDA Approves First Gene Therapy To Successfully Treat Cancer | NBC Nightly News   FDA Approval in Bladder Cancer, Breakthrough Therapy Designation in DLBCL, and More   Trump blasts recent approval rating polls as 'fake news'   Nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer   John McCamant on Anti-Cancer Therapies   Upfront Immunotherapy for NSCLC   Upfront Immunotherapy for PD-L1+ NSCLC   FDA Approval in AML, NDA Submitted in Myeloma, Clinical Hold on CAR T-cell Therapy Trials, and More   Upfront Use of Immunotherapy for NCSLC   FDA approves breakthrough CAR-T therapy for leukemia   Rucaparib for Recurrent Ovarian Cancer   Some FDA-approved drugs had safety issues later   Review on 2016 FDA Approvals, Halt on AML Trials, and More   Dr. Straus on FDA Approval of Pembrolizumab in Hodgkin Lymphoma   New drug trial heals dogs of arthritis   Gene therapy one step closer to FDA approval   Dr. Siefker-Radtke on FDA Approval of Frontline Atezolizumab in Bladder Cancer   Clarence-based company could become first to sell very low nicotine cigarette   New cancer treatment offers patients hope   Novartis Metastatic Breast Cancer Treatment   New breakthroughs in cancer research   Extended Cut: Should the Terminally Ill Have the Right to Try, Non FDA Approved Drugs?   Dr. Ascierto on Triplet of Encorafenib, Binimetinib, and Ribociclib in Melanoma   Buffalo first city in U.S. to use new ALS drug   Induction Therapy for MCL   Good Question: How Does Gene Therapy Work?   Breakthrough Designation in ALL, HIFU FDA Approval, Breast Cancer Screening Update, and More   How Does The FDA Approve New Drugs?   Ecstasy Could Soon Be Used Legally To Treat PTSD   How Can We Make Gene Therapy Effective and Affordable?   Dr. West on FDA Approval of Frontline Alectinib in ALK+ NSCLC   Mayo Clinic Cancer Center Gene and Virus Therapy Shared Resource: A Virtual Tour   Psychedelic drug being looked at to treat PTSD   Dr. Al-Kali on FDA Approval of Enasidenib in AML   Dr. Spigel on FDA Approval of Pembrolizumab/Chemo Combo in NSCLC   Dr. Reidy-Lagunes on FDA Approval of Telotristat Epitrate for Carcinoid Syndrome   FDA Approval: Frontline Ceritinib for ALK+ NSCLC   Reid: Senate Must Act To End Life-Saving Drug Shortages   Expert: New Women's Sex Drug 'A Step Forward'   Dr. Grothey on FDA Approval of Pembrolizumab in MSI-High CRC   Dr. Garcia on FDA Approval of Pembrolizumab in Bladder Cancer   Dr. Blackwell on Neratinib in HER2+ Breast Cancer   FDA Approves Frontline Nivolumab for Advanced Melanoma   The FDA Approval of Atezolizumab in Bladder Cancer   Durvalumab FDA Approval for Bladder Cancer   Local man with ALS disappointed with FDA   FDA Approval of Atezolizumab for NSCLC   Treatment for primary progressive Multiple Sclerosis   FDA Approval of Durvalumab for Bladder Cancer   FDA Approval in Carcinoid Syndrome Diarrhea, Priority Reviews in Bladder Cancer and NSCLC, and More   Is This ‘Little Pink Pill’ The Viagra For Women? | NBC Nightly News   Upfront EGFR-Targeted Therapy for NSCLC   NSCLC Immunotherapy: Transformation of Upfront Therapy   NSCLC Immunotherapy: Transformation of Upfront Therapy - O   FDA Approvals in Bladder Cancer, NSCLC, AML, HCC, and Breakthrough Designation in NSCLC   FDA Approvals in Bladder Cancer, NSCLC, AML, HCC, and a Breakthrough Designation in NSCLC   FDA Approval and Priority Review in Ovarian Cancer, End of Part B Payment Model, and More   FDA Approval in Lung Cancer, Priority Reviews in HCC and NHL, and an ODAC Recommendation   FDA Approval and 2 Priority Reviews in Bladder Cancer, and ASCO's Cancer Advance of the Year   Vivek Ramaswamy On Getting An Alzheimer's Drug Approved | Forbes   Treatment of Metastatic EGFR-Positive NSCLC   A Highly Effective Cancer Treatment Has Just Been Approved by the FDA   CLL: Factors for Upfront Therapy   21st Century Cures Act Passes and 2016 Highlights from SABCS and WCLC

Popular Today